MacroGenics, Inc.

NasdaqGS:MGNX Stock Report

Market Cap: US$102.5m

MacroGenics Management

Management criteria checks 2/4

MacroGenics' CEO is Eric Risser, appointed in Aug 2025, has a tenure of less than a year. directly owns 0.089% of the company’s shares, worth $90.70K. The average tenure of the management team and the board of directors is 3.1 years and 8.1 years respectively.

Key information

Eric Risser

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.09%
Management average tenure3.1yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets

Sep 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement

Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough

Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
User avatar

LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks

Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.

MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far

Feb 27

MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy

Dec 05

Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts

MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

May 13

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics: Trying To Build A Better Everything

Feb 15

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

CEO Compensation Analysis

How has Eric Risser's remuneration changed compared to MacroGenics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$76m

Jun 30 2025n/an/a

-US$36m

Mar 31 2025n/an/a

-US$56m

Dec 31 2024n/an/a

-US$67m

Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$136m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023n/an/a

-US$9m

Sep 30 2023n/an/a

US$50m

Jun 30 2023n/an/a

US$7m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$2mUS$461k

-US$120m

Sep 30 2022n/an/a

-US$191m

Jun 30 2022n/an/a

-US$219m

Mar 31 2022n/an/a

-US$217m

Dec 31 2021US$2mUS$428k

-US$202m

Sep 30 2021n/an/a

-US$146m

Jun 30 2021n/an/a

-US$129m

Mar 31 2021n/an/a

-US$136m

Dec 31 2020US$1mUS$431k

-US$130m

Sep 30 2020n/an/a

-US$158m

Jun 30 2020n/an/a

-US$167m

Mar 31 2020n/an/a

-US$152m

Dec 31 2019US$2mUS$388k

-US$152m

Sep 30 2019n/an/a

-US$166m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$167m

Dec 31 2018US$2mUS$393k

-US$171m

Compensation vs Market: Insufficient data to establish whether Eric's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.

CEO

Eric Risser (52 yo)

less than a year
Tenure
US$1,915,261
Compensation

Mr. Eric Blasius Risser is President, Chief Executive Officer and Director at MacroGenics, Inc. since August 13, 2025. He served as Chief Operating Officer at MacroGenics, Inc. since February 22, 2022 unti...

Leadership Team

NamePositionTenureCompensationOwnership
James Karrels
Senior VP17.6yrsUS$2.37m0.30%
$ 302.6k
Stephen Eck
Senior VP of Clinical Development & Chief Medical Officer5.4yrsUS$2.65m0.046%
$ 47.6k
Eric Risser
CEO, President & Directorless than a yearUS$1.92m0.089%
$ 90.7k
Thomas Spitznagel
Senior Vice President of Technical Operations3.1yrsUS$1.88m0.034%
$ 34.7k
Ezio Bonvini
Senior VP of Research & Chief Scientific Officer9.3yrsUS$2.29m0.20%
$ 201.6k
Jeffrey Peters
Senior VP8.5yrsno data0.022%
$ 22.2k
Steve Harig
Senior Vice President of Human Resourcesno datano datano data
Harish Krishnaswamy
Senior Vice President of Business Development & Portfolio Planningless than a yearno datano data
Frank Perabo
Vice President & Interim Head of Clinical Developmentless than a yearno datano data
Beth Smith
VP, Controller & Treasurer1.1yrsno data0.015%
$ 15.4k
3.1yrs
Average Tenure
58yo
Average Age

Experienced Management: MGNX's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Eric Risser
CEO, President & Directorless than a yearUS$1.92m0.089%
$ 90.7k
David Stump
Independent Director12.3yrsUS$155.63k0.017%
$ 17.8k
Federica O'Brien
Independent Director4.8yrsUS$170.63k0.017%
$ 17.8k
Edward Hurwitz
Independent Director21.2yrsUS$145.63k0.070%
$ 71.4k
Margaret Liu
Independent Director2.9yrsUS$145.01k0.017%
$ 17.8k
Scott Koenig
Director24.3yrsUS$6.40m1.31%
$ 1.3m
William Heiden
Independent Chairman of the Board3.6yrsUS$304.72k0.18%
$ 179.8k
Meenu Chhabra Karson
Independent Director2.9yrsUS$150.69k0.017%
$ 17.8k
Scott Jackson
Independent Director8.9yrsUS$151.57k0.017%
$ 17.8k
Jay Siegel
Independent Director8.1yrsUS$144.38k0.017%
$ 17.8k
Karen Jean Ferrante
Independent Director8.9yrsUS$145.63k0.017%
$ 17.8k
8.1yrs
Average Tenure
67yo
Average Age

Experienced Board: MGNX's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 00:26
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MacroGenics, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBarclays
Stephen V. ByrneBofA Global Research